Efficacy and safety of sarilumab in patients with active rheumatoid arthritis.

about

Efficacy and safety of sarilumab in patients with active rheumatoid arthritis.

Item

http://www.wikidata.org/entity/Q50334739

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Efficacy and safety of sarilumab in patients with active rheumatoid arthritis.

@en

Efficacy and safety of sarilumab in patients with active rheumatoid arthritis.

@nl

type

Item

label

Efficacy and safety of sarilumab in patients with active rheumatoid arthritis.

@en

Efficacy and safety of sarilumab in patients with active rheumatoid arthritis.

@nl

prefLabel

Efficacy and safety of sarilumab in patients with active rheumatoid arthritis.

@en

Efficacy and safety of sarilumab in patients with active rheumatoid arthritis.

@nl

P1476

Efficacy and safety of sarilumab in patients with active rheumatoid arthritis.

@en

P2093

April Robinson

http://www.w3.org/2001/XMLSchema#string

Delilah McCarty

http://www.w3.org/2001/XMLSchema#string

P2860

Disease-Drug Interaction of Sarilumab and Simvastatin in Patients with Rheumatoid Arthritis.

Sarilumab, a fully human monoclonal antibody against IL-6Rα in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trial.

IL-6 in inflammation, immunity, and disease

Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.

Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.

Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY

Outcome measures in inflammatory rheumatic diseases.

Sarilumab and Nonbiologic Disease-Modifying Antirheumatic Drugs in Patients With Active Rheumatoid Arthritis and Inadequate Response or Intolerance to Tumor Necrosis Factor Inhibitors.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.

P304

61-67

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1759720X17752037

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-01-11T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29492111

http://www.w3.org/2001/XMLSchema#string

P932

5802641

http://www.w3.org/2001/XMLSchema#string